In the course of reinventing, refocusing, and reinvigorating the company, Strongbridge Biopharma has reached a series of pivotal business and clinical milestones.
In December 2016, Strongbridge Biopharma acquired the U.S. rights to KEVEYIS® (dichlorphenamide). This acquisition is part of our commitment to expand our portfolio and help meet the needs of patients with rare diseases that are underdiagnosed and undertreated.
Announced closing of transaction with Novo Nordisk to transfer rights to Macrilen™ (macimorelin) in the United States and Canada
Launched Macrilen (macimorelin) for Adult Growth Hormone Deficiency
Acquired Macrilen (macimorelin) from Aeterna Zentaris for the diagnosis of Adult Growth Hormone Deficiency
Last patient enrolled (LPI) in phase 3 SONICS trial of RECORLEV (levoketoconazole) for endogenous Cushing's syndrome
Launched KEVEYIS (dichlorphenamide) for Primary Periodic Paralysis
Acquired KEVEYIS (dichlorphenamide) from Taro Pharmaceutical Industries for Primary Periodic Paralysis
Acquired veldoreotide, being studied for acromegaly, from Aspireo Pharmaceuticals
First patient enrolled in phase 3 SONICS trial of RECORLEV in endogenous Cushing's syndrome
RECORLEV received EU orphan drug designation
RECORLEV received US orphan drug designation
Pivoted RECORLEV focus from diabetes to Cushing's syndrome
Please see KEVEYIS Important Safety Information and Full Prescribing Information. Please see Macrilen Important Safety Information and Full Prescribing Information.
The safety and efficacy of RECORLEV™ (levoketoconazole) and veldoreotide have not been established.
© 2019 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V15 01/2019
900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200
[email protected]